Journal Highlight : Targeted Cancer Therapy
The journal welcomes scholarly contributions related to the development, evaluation, and clinical application of targeted therapeutic strategies for cancer treatment. This section focuses on research that advances precision-based oncology approaches by targeting specific molecular pathways, genetic alterations, and tumor-associated biomarkers to improve therapeutic effectiveness and patient outcomes.
The journal encourages submissions in areas including Targeted Oncology Therapies, Molecularly Targeted Drugs, Precision Cancer Medicine, Cancer Biomarker-Guided Therapy, Small Molecule Inhibitors, Monoclonal Antibody Therapies, Tyrosine Kinase Inhibitors, Hormone-Targeted Therapies, and Signal Transduction Pathway Inhibition. Research related to Cancer Genomics and Therapeutic Targets, Companion Diagnostics, Targeted Drug Delivery Systems, Combination Targeted Therapies, Nanotechnology-Based Cancer Therapies, and Personalized Treatment Strategies is also welcomed.
Submissions focusing on Therapeutic Resistance Mechanisms, Predictive and Prognostic Biomarkers, Clinical Trials in Targeted Therapy, Pharmacogenomics, Translational Oncology, AI and Bioinformatics in Precision Therapeutics, Targeted Immunotherapy Approaches, and Treatment Optimization in Solid and Hematologic Malignancies are encouraged. The journal also welcomes studies investigating molecular determinants of therapeutic response, toxicity management, and long-term outcomes associated with targeted cancer treatments.
Accepted manuscript types include Original Research Articles, Systematic Reviews, Meta-Analyses, Experimental and Preclinical Studies, Clinical Studies, Translational Research Articles, Clinical Trial Reports, and Technology and Methodology Articles that contribute to advancements in targeted cancer therapy and precision oncology.
Through this focus area, the journal aims to support research that advances molecularly targeted cancer treatments, improves therapeutic precision and safety, enhances personalized oncology care, and contributes to innovative and evidence-based cancer management worldwide.
